`Patent No. 6,852,689
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`____________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`____________
`
`AGILA SPECIALTIES INC. and MYLAN PHARMACEUTICALS INC.,
`
`Petitioners
`
`v.
`
`CUBIST PHARMACEUTICALS, INC.,
`
`Patent Owner
`
`____________
`
`
`Case IPR2015-00132
`
`Patent 6,852,689
`
`____________
`
`
`
`PATENT OWNER MANDATORY NOTICES
`UNDER 37 C.F.R. § 42.8
`
`
`
`
`
`1
`
`
`
`
`
`
`
`
`
`Case IPR2015-00132
`Patent No. 6,852,689
`
`
`
`I. Real Party-in-Interest
`
`The real party-in-interest is Cubist Pharmaceuticals, Inc. (“Cubist”), the
`owner of U.S. Pat. No. 6,852,689 (“the ‘689 patent”).
`
`II. Related Matters
`
`In accordance with 37 C .F .R. § 42.8 (b)(2), Cubist identifies the following
`related matters:
`
`Cubist Pharmaceuticals, Inc. v. Hospira, Inc., 1:12-cv-00367-GMS (D.Del.)
`Cubist Pharmaceuticals, Inc. v. Strides Inc. and Agila Specialties Private
`Ltd., 1:13-cv-01679-GMS (D.Del.)
`Cubist Pharmaceuticals, Inc. v. Fresenius-Kabi USA LLC, 1:14-cv-00914-
`GMS (D.Del.)
`Cubist Pharmaceuticals, Inc. v. Strides Inc. and Agila Specialties Private
`Ltd., 1:13-cv-06016-NLH-JS (D.N.J.) (Terminated)
`Cubist Pharmaceuticals, Inc. v. Teva Parenteral Medicines, Inc., et al.,
`1:09-cv-00189-GMS (D. Del) (Terminated)
`Agila Specialties Inc. and Mylan Pharmaceuticals, Inc. v. Cubist
`Pharmaceuticals, Inc., IPR2015-00131 (PTAB)
`
`Frenenius-Kabi USA LLC v. Cubist Pharmaceuticals, Inc., IPR2015-00223
`(PTAB)
`
`Frenenius-Kabi USA LLC v. Cubist Pharmaceuticals, Inc., IPR2015-00227
`(PTAB)
`
`US Application Serial No. 60/101,828
`US Application Serial No. 60/125,750
`US Application Serial No. PCT/US99/22366
`US Application Serial No. 09/406,568
`
`
`
`2
`
`
`
`Case IPR2015-00132
`Patent No. 6,852,689
`
`
`
`US Application Serial No. 10/082,544
`
`III. Counsel
`
`Lead Counsel
`William DeVaul wdevaul
`Registration No. 42,483
`Cubist Pharmaceuticals, Inc.
`65 Hayden Ave.
`Lexington, MA 02421
`(781) 860-8559
`William.DeVaul@cubist.com
`
`
`IV. Service Information
`
`Backup Counsel
`Henry H. Gu
`Registration No. 55,227
`Cubist Pharmaceuticals, Inc.
`65 Hayden Ave.
`Lexington, MA 02421
`(781) 860-8351
`Henry.Gu@cubist.com
`
`Please direct all correspondence to lead counsel and backup counsel at the
`contact information above. Cubist consents to service by electronic mail at all of
`the following email addresses:
`
`William.DeVaul@cubist.com
`
`Henry.Gu@cubist.com
`
`While email service is preferred, Cubist will accept service by U.S. Mail or
`hand-delivery at:
`
`Cubist Pharmaceuticals, Inc.
`65 Hayden Ave.
`Lexington, MA 02421
`Phone: (781) 860-8351
`Fax: (781) 860-1407
`
`
`
`3
`
`
`
`Case IPR2015-00132
`Patent No. 6,852,689
`
`
`
`
`V. Patent Owner’s Preliminary Response
`
`Cubist reserves the right to file a preliminary response at a later date.
`
`Respectfully Submitted,
`
`/Henry H. Gu/
`
`Henry H. Gu
`Registration No. 55,227
`Cubist Pharmaceuticals, Inc.
`65 Hayden Ave.
`Lexington, MA 02421
`
`
`
`4
`
`
`
`
`
`
`
`
`
`
`
`Case IPR2015-00132
`Patent No. 6,852,689
`
`Certificate of Service
`
`
`
`I hereby certify that on November 13, 2014, I caused a true and correct copy
`of the following material:
`
`• Patent Owner Mandatory Notices Under 37 C.F.R. §42.8
`
`to be served via email on the following attorneys for Petitioners:
`
`Steven W. Parmelee
`sparmelee@wsgr.com
`Peter R. Munson
`pmunson@wsgr.com
`Lori P .Westin
`lwestin@wsgr.com
`
`
`
`
`
`
`
`
`
`
`
`
`
`Respectfully Submitted,
`
`/Henry H. Gu/
`
`Henry H. Gu
`Registration No. 55,227
`Cubist Pharmaceuticals, Inc.
`65 Hayden Ave.
`Lexington, MA 02421
`
`
`
`5
`
`
`
`